Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (P41)
Closed Posted
- Opportunity number
- RFA-HL-17-033
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.121 Oral Diseases and Disorders Research
- 93.173 Research Related to Deafness and Communication Disorders
- 93.233 National Center on Sleep Disorders Research
- 93.242 Mental Health Research Grants
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- 93.350 National Center for Advancing Translational Sciences
- 93.837 Cardiovascular Diseases Research
- 93.838 Lung Diseases Research
- 93.839 Blood Diseases and Resources Research
- 93.840 Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- Funding instrument
- Grant
- Categories
-
- Food and Nutrition
- Health
- Eligible applicants
-
- Tribal Governments (Federally Recognized)
- Small Businesses
- 501(c)(3) Nonprofits
- City/Township Governments
- Tribal Organizations (Not Federally Recognized)
- Special District Governments
- Higher Education Inst. (Public)
- Non-501(c)(3) Nonprofits
- Public or Indian Housing Auth.
- Independent School Districts
- County Governments
- State Governments
- Other
- For Profit Organizations
- Higher Education Inst. (Private)
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
The National Institutes of Health (NIH) and participating NIH Institutes and Centers (ICs) and the U.S. Food and Drug Administration (FDA), through this Funding Opportunity Announcement (FOA), invite revision applications from investigators with active P41 research project awards that will support clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. A competing revision is a request for an increase in support in a current budget period for expansion of the project's approved scope or research protocol. These revision applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of product manufacturing, quality, safety, or effectiveness.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Files
| File | Type | Posted |
|---|---|---|
| oppRFA-HL-17-033-cidFORMS-D-instructions.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity